MedPath

Pfizer-BioNTech Launches Landmark Phase 3 Trial for mRNA-Based Influenza Vaccine

• Pfizer and BioNTech have initiated a 25,000-participant Phase 3 trial for their mRNA-based quadrivalent seasonal influenza vaccine, marking the first such advanced trial in the field.

• The novel vaccine targets four WHO-predicted flu strains for the 2022/23 northern hemisphere season, potentially offering advantages in production speed and efficacy over traditional vaccines.

• Current seasonal flu vaccines typically achieve 40-60% efficacy, while causing 290,000-650,000 respiratory deaths globally annually, highlighting the significant need for improved vaccination options.

In a significant advancement for vaccine technology, Pfizer and BioNTech have commenced dosing patients in a groundbreaking Phase 3 trial of their mRNA-based seasonal influenza vaccine. This milestone represents the first Phase 3 efficacy trial of an mRNA flu vaccine, potentially revolutionizing how we approach seasonal influenza prevention.
The large-scale study, involving 25,000 subjects, evaluates a nucleoside-modified mRNA (modRNA) quadrivalent vaccine designed to combat four influenza strains identified by the World Health Organization (WHO) as likely threats for the 2022/23 northern hemisphere season. The trial will measure the vaccine's performance against currently approved inactivated vaccines.

Advancing Beyond Traditional Vaccine Technology

The development leverages the same mRNA technology platform that proved successful in the rapid creation and deployment of Comirnaty, the companies' COVID-19 vaccine. This approach offers distinct advantages over conventional cell culture or recombinant techniques, particularly in addressing influenza's rapid mutation patterns.
Traditional flu vaccines face significant challenges in strain prediction and manufacturing timelines. The mRNA platform's ability to quickly modify vaccine compositions could prove crucial when annual strain predictions prove inaccurate, offering a more responsive approach to viral mutations.

Market Landscape and Competition

The race to develop mRNA-based flu vaccines has attracted several major pharmaceutical players. Moderna has already fully enrolled a 6,000-subject Phase 3 study of its quadrivalent vaccine candidate mRNA-1010 in the southern hemisphere. The company is also exploring combination vaccines, including a dual COVID-19/flu shot and a triple vaccine adding RSV protection.
Other competitors include Sanofi, which reported positive Phase 1/2 results for their SP0273 vaccine, and CureVac partnering with GSK in Phase 1 trials. This competitive landscape underscores the industry's recognition of mRNA technology's potential in addressing seasonal influenza.

Public Health Impact

The development of more effective flu vaccines could have substantial public health implications. Current statistics reveal the devastating impact of influenza:
  • Annual U.S. hospitalizations: 140,000 to 710,000
  • Annual U.S. deaths: 12,000 to 52,000
  • Economic impact in the U.S.: Approximately $25 billion yearly
  • Global severe cases: 3 to 5 million
  • Global annual respiratory deaths: 290,000-650,000

Potential Advantages of mRNA Technology

Current seasonal flu vaccines typically achieve only 40% to 60% protective efficacy. While these vaccines can reduce infection severity, there's significant room for improvement. The mRNA platform's potential for higher efficacy, combined with its rapid development capabilities, could transform seasonal flu prevention strategies.
The technology's adaptability could prove particularly valuable in years when circulating strains don't match vaccine predictions, allowing for quicker adjustments to vaccine composition. This flexibility, coupled with potentially enhanced efficacy, represents a significant advancement in influenza prevention strategies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Places Moderna's Norovirus Vaccine Trial on Clinical Hold Following Guillain-Barré Case

Moderna's Phase 3 trial for its trivalent norovirus vaccine has been placed on FDA clinical hold following a reported case of Guillain-Barré syndrome.
The Northern Hemisphere arm of the two-season study is fully enrolled, with Southern Hemisphere enrollment in preparation phase.

Novavax Launches Phase 3 Trial for COVID-19-Influenza Combination Vaccine

Novavax has initiated a Phase 3 clinical trial for its COVID-19-Influenza Combination (CIC) vaccine and a stand-alone influenza vaccine, targeting adults aged 65 and older. The trial aims to evaluate the immunogenicity and safety of these vaccines compared to existing options. Novavax is also exploring an accelerated approval pathway with the U.S. FDA.

Inflammatix Launches Clinical Trial for mRNA-Based Infection Diagnostic, TriVerity

Inflammatix initiates the TIMED trial (NCT06637904) to assess its TriVerity test for managing patients with suspected acute infection or sepsis.
The TriVerity test analyzes 29 messenger RNAs (mRNAs) to provide rapid insights into the body's immune response to infection, delivering results in about 30 minutes.

Phase 3 Trial Aims to Combat Norovirus with mRNA Vaccine in Adults

A Phase 3 clinical trial, Nova 301, is underway to evaluate an investigational mRNA vaccine's efficacy against norovirus in adults aged 18 and older.
The trial seeks to enroll approximately 25,000 participants globally, comparing the investigational vaccine to a placebo jab over a 25-month period.

Norovirus Vaccine Development Advances with mRNA and Oral Tablet Candidates

Moderna's mRNA-1403 vaccine demonstrated strong antibody responses against prevalent norovirus genotypes in early-phase trials, utilizing similar technology to their COVID and RSV vaccines.
An oral tablet vaccine, VXA-G1.1-NN, showed a 29% relative reduction in norovirus infection in a phase II trial, along with reduced viral shedding, though it did not meet its primary endpoint for preventing illness.

Mater Research Initiates Trial for Novavax's Combined COVID-19 and Flu Vaccine

Mater Research in Brisbane has begun a clinical trial for a combined COVID-19 and influenza vaccine developed by Novavax.
The protein-based, non-mRNA vaccine aims to protect individuals unable to receive mRNA vaccines by using a coronavirus spike protein segment to trigger an immune response.

mRNA Vaccine Pipeline Heats Up: Late-Stage Candidates Target Flu, COVID, CMV, and Cancer

Pfizer and BioNTech are advancing an mRNA influenza vaccine, PF-07252220, demonstrating superiority over existing flu vaccines in Phase III trials.
Moderna's mRNA-1083, a combination COVID-19/influenza vaccine, showed strong immune responses in Phase III, potentially extending the sales of COVID-19 vaccines.

GSK's mRNA Influenza Vaccine Shows Promise in Phase II Trial, Advancing to Phase III

GSK's mRNA seasonal influenza vaccine candidate met pre-defined success criteria in Phase II trials for both younger and older adults, demonstrating positive immune responses against influenza A and B strains.
The mRNA platform elicited strong overall antibody titers with an acceptable safety profile, supporting its potential as a next-generation influenza vaccine.

Pfizer and BioNTech's Combination mRNA Vaccine Shows Promise Against Influenza A and COVID-19

Pfizer and BioNTech's Phase 3 trial of their combined mRNA vaccine against influenza and COVID-19 met one primary immunogenicity objective in adults aged 18-64.
The combination vaccine candidate elicited robust antibody responses against influenza A, comparable to Pfizer's quadrivalent influenza vaccine.

Reference News

[1]
Pfizer, BioNTech's mRNA flu vaccine starts phase 3 testing
pharmaphorum.com · May 21, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy